1/2

Export Ready

BQNAT

Name: BQNAT
SKU: 8516129
Price: 163.24 USD
Availability: InStock

Sold by vaishnavi injectables · Wholesaler · Kanpur Nagar, Uttar Pradesh, India

Price

₹ 163.24 /Piece

In stock

MRP ~~₹ 204.05~~

Inclusive of all taxes

You Save: ₹ 40.81

Minimum order: 1 Piece

Export Snapshot

MOQ

1 Piece

Lead time

On request

Packaging

Standard export packaging

Shelf life / longevity

As per product specification

HS Code

On request

Origin

India

Port of dispatch

On request

Export markets served

Global markets

Values shown are for vaishnavi injectables.

Compliance & Certifications

Suitable for

Importers · Distributors · Wholesalers

Kanpur Nagar Dispatch on request Verified seller

vaishnavi injectables

Wholesaler · Kanpur Nagar, Uttar Pradesh, India

Registered address: Kanpur Nagar, India. Industry: Healthcare, Medical Supplies & Pharmaceuticals > Drugs & Pharmaceuticals.

View profile All products

Established

Not shared

Employees

–

GST

09AAUFV5012F1ZX

IEC code

Not shared

Export markets

Global markets

GlobalLinker Member Since

Jul 2025

Turnover

Incorporation Type

On request

Verified Seller

Product details

What are the specifications of this product?

Overview

BQNAT = Bedaquiline-based treatment following a Negative CBNAAT test CBNAAT = Cartridge-Based Nucleic Acid Amplification Test (like GeneXpert) BQNAT regimen is used for drug-resistant TB cases when: Rifampicin resistance is detected Patient is eligible for Bedaquiline-containing regimen Confirmed MDR-TB or XDR-TB, often through Line Probe Assay (LPA) and CBNAAT BQNAT Regimen – Overview (India’s NTEP Guidelines) Core Drugs (may vary slightly): Bedaquiline (BDQ) Levofloxacin (Lfx) or Moxifloxacin (Mfx) Linezolid (Lzd) Clofazimine (Cfz) Cycloserine (Cs) Duration: 18–20 months, depending on patient response and tolerability Regular monitoring: ECG, liver function, electrolytes, adherence Used In: Patients with rifampicin-resistant TB (RR-TB) or MDR-TB If CBNAAT detects Rif resistance, and DST (Drug Susceptibility Testing) guides further drug inclusion Implemented under National TB Elimination Program (NTEP), India If you're referring to something else by BQNAT (e.g., a lab test, a program, or a specific guideline), feel free to clarify! Ask ChatGPT

Product Description

BQNAT = Bedaquiline-based treatment following a Negative CBNAAT test

CBNAAT = Cartridge-Based Nucleic Acid Amplification Test (like GeneXpert)

BQNAT regimen is used for drug-resistant TB cases when:

Rifampicin resistance is detected

Patient is eligible for Bedaquiline-containing regimen

Confirmed MDR-TB or XDR-TB, often through Line Probe Assay (LPA) and CBNAAT

BQNAT Regimen – Overview (India’s NTEP Guidelines)

Core Drugs (may vary slightly):

Bedaquiline (BDQ)

Levofloxacin (Lfx) or Moxifloxacin (Mfx)

Linezolid (Lzd)

Clofazimine (Cfz)

Cycloserine (Cs)

Duration: 18–20 months, depending on patient response and tolerability

Regular monitoring: ECG, liver function, electrolytes, adherence

Used In:

Patients with rifampicin-resistant TB (RR-TB) or MDR-TB

If CBNAAT detects Rif resistance, and DST (Drug Susceptibility Testing) guides further drug inclusion

Implemented under National TB Elimination Program (NTEP), India

If you're referring to something else by BQNAT (e.g., a lab test, a program, or a specific guideline), feel free to clarify!

Ask ChatGPT

Description provided by vaishnavi injectables.

Specifications

Regimen Type	Bedaquiline-based drug-resistant TB treatment
Target Condition	Drug-resistant tuberculosis including RR-TB, MDR-TB, XDR-TB
Diagnostic Tests Required	CBNAAT for rifampicin resistance, Line Probe Assay (LPA) for detailed drug susceptibility
Treatment Duration	18-20 months
Drugs Included	Bedaquiline, Levofloxacin/Moxifloxacin, Linezolid, Clofazimine, Cycloserine
Monitoring Requirements	ECG, liver function tests, electrolytes, drug adherence
Regulatory Program	National TB Elimination Program (NTEP), India
Administration Method	Oral medication combination regimen
Patient Monitoring Frequency	Regular intervals throughout treatment duration

Use cases

Category	Medical > Pharmaceuticals > Anti-Tuberculosis Drugs > Drug-Resistant TB Treatment Regimens
Primary application	Wholesale, distribution, and international sourcing
Brand	Not specified
Product type	Product

Logistics & handling

Lead time	On request
Packaging	As per buyer requirement
Storage condition	As recommended by supplier
Origin	India
Form	As listed by supplier

Commercials (this seller)

Minimum order	1 Piece
Lead time	On request
Payment terms	As per negotiated commercial agreement.
Checkout type	enquiry

Buyer questions

Frequently asked by buyers

Common questions B2B buyers ask before sourcing BQNAT. Answers compiled from verified sellers' commercial terms and platform data.

Q: What tests confirm patient eligibility for the BQNAT regimen?

A: Patient eligibility for BQNAT is confirmed through a negative CBNAAT test indicating rifampicin resistance, followed by drug susceptibility confirmation with Line Probe Assay (LPA).

Q: How long is the BQNAT treatment duration?

A: The BQNAT regimen is administered over 18 to 20 months depending on the patient's clinical response and drug tolerability.

Q: What drugs comprise the BQNAT regimen core?

A: The regimen core drugs include Bedaquiline, Levofloxacin or Moxifloxacin, Linezolid, Clofazimine, and Cycloserine.

Q: What monitoring is essential during BQNAT treatment?

A: Regular monitoring includes ECG for cardiac health, liver function tests, electrolyte levels, and close monitoring of medication adherence.

Q: Is BQNAT regimen aligned with any national TB program?

A: Yes, BQNAT is implemented under the Indian National TB Elimination Program (NTEP) guidelines designed for managing drug-resistant TB.

Q: Can BQNAT be used for XDR-TB cases?

A: Yes, BQNAT is suitable for extensively drug-resistant TB cases once rifampicin resistance and further susceptibility patterns are confirmed.

Question not answered? Ask sellers directly — typical response within 4 hours.